BRCA1 and breast cancer: In this study, we investigated T-96's antitumor activity on two breast cancer cell lines, SUM-1315 cell line, a highly metastatic and BRCA1 mutant TNBC cell line, and MCF-7 cell line, a lowly metastatic and ER-positive breast cancer cell line.